Wednesday, February 8, 2012 Last update: 10:34 PM
The Best of U.S. Company Technology News
Now being accepted at FreshNews.com. See our complete guidelines.
Trade Events
Affymax, Inc.
News articles for Affymax, Inc.:
Wednesday, February 8, 2012
- Affymax to Present at 14th Annual BIO CEO & Investor ConferenceAffymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company’s chief executive officer, will present at the 14th Annual BIO CEO & Investor Conference on Tuesday, February ... read more
Thursday, February 2, 2012
- Affymax Promotes Cynthia Smith to Vice President, Market Access and Commercial DevelopmentAffymax, Inc. (Nasdaq: AFFY) today announced the promotion of Cynthia Smith to vice president, market access and commercial development. Ms. Smith, who has 15 years of experience in ... read more
Wednesday, January 4, 2012
- Affymax to Webcast Analyst Briefing EventAffymax, Inc. (Nasdaq: AFFY) today announced that it will webcast an analyst briefing on Tuesday, January 10 at 7:15 a.m. PT. During the event, Affymax management will provide ... read more
Thursday, December 15, 2011
- Takeda and Affymax Provide Update on Peginesatide Commercialization Rights in JapanTakeda Pharmaceutical Company Limited (TSE:4502) and Affymax, Inc. (Nasdaq:AFFY) today announced that Takeda has decided not to commercialize peginesatide in Japan. Peginesatide is an investigational ... read more
Wednesday, December 7, 2011
- FDA Advisory Committee Voted in Favor of Benefit/Risk Profile for Peginesatide for Treatment of Anemia in Chronic Kidney Disease Patients on DialysisAffymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502), today announced that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 15 to 1, ... read more
Friday, November 11, 2011
- Affymax and Takeda Report Additional Analyses of Peginesatide Phase 3 Studies in Dialysis Patients at the American Society of Nephrology’s Kidney Week 2011Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced results from additional analyses of the EMERALD Phase 3 studies that evaluated the ... read more
Wednesday, November 9, 2011
- Affymax® Reports Third Quarter 2011 Financial ResultsAffymax, Inc. (Nasdaq:AFFY) today reported financial results for the third quarter ended September 30, 2011. The net loss for the third quarter of 2011 was $9.8 million compared ... read moreAffymax and Janssen Biotech Settle Patent DisputeAffymax, Inc. (Nasdaq:AFFY) today announced that it has reached a global settlement agreement with Janssen Biotech, Inc. (a subsidiary of Johnson & Johnson) and certain of its affiliated ... read more
Monday, October 24, 2011
- Affymax Announces FDA Advisory Committee to Review PeginesatideAffymax, Inc. (Nasdaq:AFFY) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for peginesatide proposed ... read more
Monday, October 10, 2011
- Affymax and Takeda to Present Peginesatide Data at the American Society of Nephrology Kidney Week 2011Affymax, Inc. (Nasdaq:AFFY) and Takeda Pharmaceuticals Global Research & Development Center, Inc., U.S., today announced data from multiple studies of peginesatide (formerly known as Hematide™) have been accepted ... read more
Wednesday, August 31, 2011
- Affymax Announces Upcoming Webcasts and Conference ParticipationAffymax, Inc. (Nasdaq:AFFY) today announced the company’s participation at the following investor conferences during the month of September. ... read more